CFDE Data Portal | Search RDM1P2

	Label	Description
	RDM1P2 Gene (Entity type)	ENSG00000266497 - RDM1 pseudogene 2
	GSE114492 GSE153671 KMT2D inhibition 6 v 8 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE203329 HCC knockout 2 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE130401 trametinib YAP 6 v 0 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE111247 temozolomide LN-308 11 v 10 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE210150 crizotinib cardiac muscle cell 0 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE168604 GSE183859 selumetinib 1 v 0 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE195568 palbociclib 3 v 10 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GTEx Esophagus 20-29 vs 40-49 Down Gene Set (Entity type)	A Gene Set from GTEx
	GTEx Nerve 20-29 vs 30-39 Down Gene Set (Entity type)	A Gene Set from GTEx

RDM1P2

ENSG00000266497 - RDM1 pseudogene 2

GSE114492 GSE153671 KMT2D inhibition 6 v 8 human up

A Gene Set from LINCS

GSE203329 HCC knockout 2 v 1 human up

A Gene Set from LINCS

GSE130401 trametinib YAP 6 v 0 human dn

A Gene Set from LINCS

GSE111247 temozolomide LN-308 11 v 10 human up

A Gene Set from LINCS

GSE210150 crizotinib cardiac muscle cell 0 v 1 human up

A Gene Set from LINCS

GSE168604 GSE183859 selumetinib 1 v 0 human dn

A Gene Set from LINCS

GSE195568 palbociclib 3 v 10 human dn

A Gene Set from LINCS

GTEx Esophagus 20-29 vs 40-49 Down

A Gene Set from GTEx

GTEx Nerve 20-29 vs 30-39 Down

A Gene Set from GTEx

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.